Health AI Central
Share:
Peer-Reviewed Publication
Clin Lung Cancer2025;26(6):511-514.September 1, 2025Journal Article

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.

J Nicholas Bodor1, Jonathan Dowell2, Joseph Treat3, Janakiraman Subramanian4, Nihal Abdulla5, Eric Lee6, Kamlesh Sankhala7, Chun-Hui Lee8, Go Makimoto9, Eisaku Miyauchi10, Kartik Konduri11, Hajime Asahina12, Shuji Murakami13, Yueh-Feng Wen14, Yung-Hung Luo15, Shan Yueh Chang16, Reginald Ewesuedo17, Jianli Zhou17, Yasushi Goto18
1Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address: joseph.bodor@fccc.edu.
2Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX.
3Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA.
4Thoracic Oncology Program, Inova Schar Cancer Institute, Fairfax, VA.
5Department of Hematology/Oncology, Cancer and Blood Specialty Clinic, Los Alamitos, CA.
6Los Angeles Cancer Network, Fountain Valley, CA.
7Precision NextGen Oncology and Research Center, Beverly Hills, CA.
8Division of Medical Oncology, National Cheng Kung University Hospital, Tainan, Taiwan.
9Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
10Department of Respiratory Medicine, Tohoku University Hospital, Sendai-shi, Japan.
11Department of Hematology and Medical Oncology, Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX.
12Department of Respiratory Medicine, Hokkaido Cancer Center, Sapporo-Shi, Japan.
13Department of Respiratory Medicine, Kanagawa Cancer Center Hospital, Yokohama-Shi, Japan.
14Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan.
15Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
16Division of Pulmonary and Critical Medicine, Department of Internal Medicine, Tri-service General Hospital, National Defense Medical Center, Taipei, Taiwan.
17Lantern Pharma, Dallas, TX.
18Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
PubMed DOI

Abstract

INTRODUCTION: Most patients with non-small cell lung cancer (NSCLC) who have never smoked possess tumors bearing tyrosine kinase oncogenes. While such tumors may exhibit robust responses to front-line tyrosine inhibitors (TKIs), disease progression is inevitable. Subsequent available therapies confer limited benefit, thus developing effective treatments for these patients remains a critical need.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.